These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 3809855)

  • 1. [Rapid modification of the symptomatology of progressive forms of multiple sclerosis by plasma exchange].
    Trouillas P; Neuschwander P; Trémisi JP
    Rev Neurol (Paris); 1986; 142(8-9):689-95. PubMed ID: 3809855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
    Hauser SL; Dawson DM; Lehrich JR; Beal MF; Kevy SV; Propper RD; Mills JA; Weiner HL
    N Engl J Med; 1983 Jan; 308(4):173-80. PubMed ID: 6294517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study.
    Kaynar L; Altuntas F; Aydogdu I; Turgut B; Kocyigit I; Hacioglu SK; Ismailogullari S; Turgut N; Erkurt MA; Sari I; Oztekin M; Solmaz M; Eser B; Ersoy AO; Unal A; Cetin M
    Transfus Apher Sci; 2008 Apr; 38(2):109-15. PubMed ID: 18331814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months.
    Llufriu S; Castillo J; Blanco Y; Ramió-Torrentà L; Río J; Vallès M; Lozano M; Castellà MD; Calabia J; Horga A; Graus F; Montalban X; Saiz A
    Neurology; 2009 Sep; 73(12):949-53. PubMed ID: 19770470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic plasma exchange combined with immunomodulating agents in secondary progressive multiple sclerosis patients.
    Grapsa E; Triantafyllou N; Rombos A; Lagouranis A; Dimopoulos MA
    Ther Apher Dial; 2008 Apr; 12(2):105-8. PubMed ID: 18387157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age at disability milestones in multiple sclerosis.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):595-605. PubMed ID: 16415309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
    Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
    Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical aspects of fatigue in multiple sclerosis.
    Bergamaschi R; Romani A; Versino M; Poli R; Cosi V
    Funct Neurol; 1997; 12(5):247-51. PubMed ID: 9439942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoprinosine in multiple sclerosis treatment: a preliminary study.
    Mazzarello P; Rocchelli B; Poloni M; Delodovici M; Pinelli P
    Schweiz Arch Neurol Neurochir Psychiatr; 1982; 131(2):175-9. PubMed ID: 6187064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis.
    Trebst C; Reising A; Kielstein JT; Hafer C; Stangel M
    Blood Purif; 2009; 28(2):108-15. PubMed ID: 19521072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
    Baier ML; Cutter GR; Rudick RA; Miller D; Cohen JA; Weinstock-Guttman B; Mass M; Balcer LJ
    Neurology; 2005 Mar; 64(6):992-5. PubMed ID: 15781814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functionality or aesthetics? A pilot study of music therapy in the treatment of multiple sclerosis patients.
    Aldridge D; Schmid W; Kaeder M; Schmidt C; Ostermann T
    Complement Ther Med; 2005 Mar; 13(1):25-33. PubMed ID: 15907675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis: relapses and timing of remissions.
    Iuliano G; Napoletano R; Esposito A
    Eur Neurol; 2008; 59(1-2):44-8. PubMed ID: 17917457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of multiple sclerosis with IgG immunotherapy.
    Schuller E; Lambin P; Deloche G
    Pathol Biol (Paris); 1996 Oct; 44(8):710-5. PubMed ID: 8977930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma S100beta and NSE levels and progression in multiple sclerosis.
    Koch M; Mostert J; Heersema D; Teelken A; De Keyser J
    J Neurol Sci; 2007 Jan; 252(2):154-8. PubMed ID: 17187827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary reports on hyperbaric oxygen therapy in multiple sclerosis.
    Ulewicz K; Dolmierski R; Masłowski J; Michniewski P; Kierznikowicz B; Wisłocka I; Sićko Z; Olszański R
    Bull Inst Marit Trop Med Gdynia; 1988; 39(3-4):197-204. PubMed ID: 3270584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis update.
    Mayr WT; Rodriguez M
    Minn Med; 2002 Jun; 85(6):36-9. PubMed ID: 12092437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
    Ozakbas S; Cagiran I; Ormeci B; Idiman E
    J Neurol Sci; 2004 Mar; 218(1-2):3-7. PubMed ID: 14759626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose methylprednisolone infusions in relapsing and in chronic progressive multiple sclerosis patients. One year follow-up.
    Bergamaschi R; Versino M; Raiola E; Citterio A; Cosi V
    Acta Neurol (Napoli); 1993 Feb; 15(1):33-43. PubMed ID: 8456594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.